Company: HYEX
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001096906-25-000753
Chunk: 13

Company: HEALTHY EXTRACTS INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 7
Chunk 13
---
 net cash used in operating activities for the three months ended March 31, 2024 consisted of our net loss of $861,259, offset in part by our change in fair value on derivative liability of $756,628.

30

Investing Activities

We had zero cash flows provided by investing activities for the three months ended March 31, 2025 and 2024.

Financing Activities

Our net cash used in financing activities for the three months ended March 31, 2025 was $(53,243), compared to net cash provided by financing activities of $49,146 for the three months ended March 31, 2024. Our net cash used in financing activities consisted primarily of payments for repayment of convertible debt of $37,212 and payments for repayment of notes payable-related party of $13,402.

ITEM 3Quantitative and Qualitative Disclosures About Market Risk 

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 4Controls and Procedures 

(a)Disclosure Controls and Procedures  

We conducted an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of March 31, 2025, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities Exchange Commission’s rules and forms, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2025, our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses identified and described in our Annual Report on Internal Control Over Financial Reporting filed in our Annual Report on Form 10-K.

Our principal executive officers do not expect that our disclosure controls or internal controls will prevent all errors and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives and our principal executive